title: DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children.
abstract: This multicentre study was designed to establish the reactogenicity and immunogenicity profiles of primary and booster vaccination with diphtheria, tetanus, and pertussis whole-cell-hepatitis B/Haemophilus influenzae type-b (DTPw-HB/Hib) administered as either a syringe mix or as separate injections in 400 Latin American children. Both vaccine regimens were equally well tolerated and elicited post-primary excellent seropositivity rates at or close to 100% for all five component antigens. With regard to HB, 100% of subjects in the combined vaccination group, and 98.8% subjects in the separate injection vaccination group reached seroprotective antibody concentrations (>or=10 mIU/ml) 1 month after the primary vaccination course. Equally high anti-PRP antibody concentrations were reached 1 month after vaccination, with 100% of seroprotected subjects in the combined vaccination group (antibody concentrations >or=0.15 microg/ml), against 99.4% in the separate injection vaccination group. Seroprotective anti-HBs and anti-PRP antibody concentration levels persisted approximately 1 year after the primary vaccination course, just prior to booster vaccination. Finally, a significant increase of all antibody concentrations could be observed after the booster vaccination, since all but one subject in the separate injection vaccination group had protective levels of anti-HBs and anti-PRP antibodies 1 month after the booster dose. These results suggest that the combination of DTPw-HB and Hib vaccines provides an effective means for increasing vaccine coverage in childhood vaccination programmes.
authors.affiliation: Departamento de Medicina Experimental, Facultad de Medicina UNAM and Conrejo Nacional de Vacunación, Ministry of Health, Mexico. jisantos@supernet.com.mx
authors.forename: José Ignacio
authors.initials: JI
authors.lastname: Santos
authors.forename: Amando
authors.initials: A
authors.lastname: Martin
authors.forename: Tirza
authors.initials: T
authors.lastname: De Leon
authors.forename: Luis
authors.initials: L
authors.lastname: Rivera
authors.forename: Maria Elisa García
authors.initials: ME
authors.lastname: Gaitán
authors.forename: Carlos
authors.initials: C
authors.lastname: Del Rio
authors.forename: Gabriel
authors.initials: G
authors.lastname: Oselka
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Cervantes
authors.forename: Pilar
authors.initials: P
authors.lastname: Rubio
authors.forename: Sue Ann Costa
authors.initials: SA
authors.lastname: Clemens
authors.forename: João Silva
authors.initials: JS
authors.lastname: de Mendonça
mesh_terms: D000907:Antibodies, Bacterial / Q000096:biosynthesis; D016667:Bacterial Capsules; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D017325:Hepatitis B Vaccines; D011135:Polysaccharides, Bacterial; D017778:Vaccines, Combined